論文
(5) 癌関連(cancer)

Global, cancer-specific microRNA cluster hypomethylation was functionally associated with the development of non-B non-C hepatocellular carcinoma.
Nojima M, Matsui T, Tamori A, Kubo S, Shirabe K, Kimura K, Shimada M, Utsunomiya T, Kondo Y, Iio E, Naito Y, Ochiya T, Tanaka Y.
Mol Cancer. 2016 Apr 30;15(1):31.
https://pubmed.ncbi.nlm.nih.gov/27137948/

Comparison of Characterization in Two-Dimensional and Three-Dimensional Canine Mammary Gland Tumor Cell Models.
Osaki T, Sunden Y, Warita K, Okamoto Y.
Yonago Acta Med. 2023 Feb 20;66(1):7-18.
https://pubmed.ncbi.nlm.nih.gov/36811028/

Zranb1-mutant mice display abnormal colonic mucus production and exacerbation of DSS-induced colitis.
Tamura A, Ito G, Matsuda H, Nibe-Shirakihara Y, Hiraoka Y, Kitagawa S, Hiraguri Y, Nagata S, Aonuma E, Otsubo K, Nemoto Y, Nagaishi T, Watanabe M, Okamoto R, Oshima S.
Biochem Biophys Res Commun. 2022 Nov 5;628:147-154.
https://pubmed.ncbi.nlm.nih.gov/36087511/

Serum microRNAs as new criteria for referral to early palliative care services in treatment-naïve advanced cancer patients.
Miura T, Mitsunaga S, Matsuzaki J, Takizawa S, Kato K, Ochiai A, Ochiya T.
Oncotarget. 2022 Dec 17;13:1341-1349. doi: 10.18632/oncotarget.28327.
https://pubmed.ncbi.nlm.nih.gov/36528878/

Circulating microRNAs: Challenges with their use as liquid biopsy biomarkers.
Takizawa S, Matsuzaki J, Ochiya T.
Cancer Biomark. 2022;35(1):1-9. doi: 10.3233/CBM-210223.
https://pubmed.ncbi.nlm.nih.gov/35786647/

Comprehensive serum and tissue microRNA profiling in dedifferentiated liposarcoma.
Kohama I, Asano N, Matsuzaki J, Yamamoto Y, Yamamoto T, Takahashi RU, Kobayashi E, Takizawa S, Sakamoto H, Kato K, Fujimoto H, Chikuda H, Kawai A, Ochiya T.
Oncol Lett. 2021 Aug;22(2):623. doi: 10.3892/ol.2021.12884. Epub 2021 Jun 29.
https://pubmed.ncbi.nlm.nih.gov/34285721/

Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
Yoshida K, Yokoi A, Matsuzaki J, Kato T, Ochiya T, Kajiyama H, Yamamoto Y.
Cancer Sci. 2021 Dec;112(12):4977-4986. doi: 10.1111/cas.15154. Epub 2021 Oct 19.
https://pubmed.ncbi.nlm.nih.gov/34618992/

ΔNp63α induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.
Amin R, Morita-Fujimura Y, Tawarayama H, Semba K, Chiba N, Fukumoto M, Ikawa S.
Mol Oncol. 2016 Apr;10(4):575-93. doi: 10.1016/j.molonc.2015.11.009. Epub 2015 Nov 24.
https://pubmed.ncbi.nlm.nih.gov/26704768/

Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth.
Toyota Y, Iwama H, Kato K, Tani J, Katsura A, Miyata M, Fujiwara S, Fujita K, Sakamoto T, Fujimori T, Okura R, Kobayashi K, Tadokoro T, Mimura S, Nomura T, Miyoshi H, Morishita A, Kamada H, Yoneyama H, Okano K, Suzuki Y, Masaki T.
Int J Oncol. 2015 Oct;47(4):1293-302. doi: 10.3892/ijo.2015.3118. Epub 2015 Aug 7.
https://pubmed.ncbi.nlm.nih.gov/26252371/

Prognostic relevance of miR-137 in patients with hepatocellular carcinoma.
Sakabe T, Azumi J, Umekita Y, Toriguchi K, Hatano E, Hirooka Y, Shiota G.
Liver Int. 2017 Feb;37(2):271-279. doi: 10.1111/liv.13213. Epub 2016 Aug 16.
https://pubmed.ncbi.nlm.nih.gov/27473646/

MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus.
Okumura T, Fujii T, Terabayashi K, Kojima T, Takeda S, Kashiwada T, Toriyama K, Hijioka S, Miyazaki T, Yamamoto M, Tanabe S, Shirakawa Y, Furukawa M, Honma Y, Hoshino I, Nabeya Y, Yamaguchi H, Uemoto S, Shimada Y, Matsubara H, Ozawa S, Makuuchi H, Imamura M.
Oncol Lett. 2023 May 12;26(1):276. doi: 10.3892/ol.2023.13862. eCollection 2023 Jul.
https://pubmed.ncbi.nlm.nih.gov/37274462/

Specific delivery of microRNA93 into HBV-replicating hepatocytes downregulates protein expression of liver cancer susceptible gene MICA.
Ohno M, Otsuka M, Kishikawa T, Shibata C, Yoshikawa T, Takata A, Muroyama R, Kowatari N, Sato M, Kato N, Kuroda S, Koike K.
Oncotarget. 2014 Jul 30;5(14):5581-90. doi: 10.18632/oncotarget.2143.
https://pubmed.ncbi.nlm.nih.gov/25026299/

Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
Maekawa A, Kohashi K, Kuda M, Iura K, Ishii T, Endo M, Nakatsura T, Iwamoto Y, Oda Y.
BMC Cancer. 2016 Jul 20;16:511. doi: 10.1186/s12885-016-2542-4.
https://pubmed.ncbi.nlm.nih.gov/27439614/

Prognostic relevance of miR-137 in patients with hepatocellular carcinoma.
Sakabe T, Azumi J, Umekita Y, Toriguchi K, Hatano E, Hirooka Y, Shiota G.
Liver Int. 2017 Feb;37(2):271-279. doi: 10.1111/liv.13213. Epub 2016 Aug 16.
https://pubmed.ncbi.nlm.nih.gov/27473646/

DKK3 Overexpression Increases the Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells.
Katase N, Nishimatsu SI, Yamauchi A, Yamamura M, Terada K, Itadani M, Okada N, Hassan NMM, Nagatsuka H, Ikeda T, Nohno T, Fujita S.
Oncol Res. 2018 Jan 19;26(1):45-58. doi: 10.3727/096504017X14926874596386. Epub 2017 May 4.
https://pubmed.ncbi.nlm.nih.gov/28470144/

Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system.
Saito Y, Nakaoka T, Muramatsu T, Ojima H, Sukeda A, Sugiyama Y, Uchida R, Furukawa R, Kitahara A, Sato T, Kanai Y, Saito H.
Sci Rep. 2018 Feb 12;8(1):2821. doi: 10.1038/s41598-018-21121-6.
https://pubmed.ncbi.nlm.nih.gov/29434290/

FGFRL1 deficiency reduces motility and tumorigenic potential of cells derived from oesophageal squamous cell carcinomas.
Takei Y, Matsumura T, Watanabe K, Nakamine H, Sudo T, Shimizu K, Shimada Y.
Oncol Lett. 2018 Jul;16(1):809-814. doi: 10.3892/ol.2018.8739. Epub 2018 May 18.
https://pubmed.ncbi.nlm.nih.gov/29963148/

Polyamine flux suppresses histone lysine demethylases and enhances ID1 expression in cancer stem cells.
Tamari K, Konno M, Asai A, Koseki J, Hayashi K, Kawamoto K, Murai N, Matsufuji S, Isohashi F, Satoh T, Goto N, Tanaka S, Doki Y, Mori M, Ogawa K, Ishii H.
Cell Death Discov. 2018 Nov 13;4:104. doi: 10.1038/s41420-018-0117-7. eCollection 2018.
https://pubmed.ncbi.nlm.nih.gov/30455990/

A tissue microRNA signature that predicts the prognosis of breast cancer in young women.
Hironaka-Mitsuhashi A, Matsuzaki J, Takahashi RU, Yoshida M, Nezu Y, Yamamoto Y, Shiino S, Kinoshita T, Ushijima T, Hiraoka N, Shimizu C, Tamura K, Ochiya T.
PLoS One. 2017 Nov 15;12(11):e0187638. doi: 10.1371/journal.pone.0187638. eCollection 2017.
https://pubmed.ncbi.nlm.nih.gov/29141042/

Unique circulating microRNAs in relation to EGFR mutation status in Japanese smoker male with lung adenocarcinoma.
Ito S, Kamoto Y, Sakai A, Sasai K, Hayashi T, Toyooka S, Katayama H.
Oncotarget. 2017 Sep 30;8(70):114685-114697. doi: 10.18632/oncotarget.21425. eCollection 2017 Dec 29.
https://pubmed.ncbi.nlm.nih.gov/29383112/

Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients.
Fujita K, Mimura S, Iwama H, Nakahara M, Oura K, Tadokoro T, Nomura T, Tani J, Yoneyama H, Morishita A, Oryu M, Himoto T, Nishitsuji H, Shimotohno K, Omata M, Masaki T.
Int J Mol Sci. 2018 Jul 2;19(7):1940. doi: 10.3390/ijms19071940.
https://pubmed.ncbi.nlm.nih.gov/30004437/

Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery.
Akazawa Y, Mizuno S, Fujinami N, Suzuki T, Yoshioka Y, Ochiya T, Nakamoto Y, Nakatsura T.
Sci Rep. 2019 Apr 11;9(1):5925. doi: 10.1038/s41598-019-42392-7.
https://pubmed.ncbi.nlm.nih.gov/30976046/

The Interaction Between Long Non-coding RNA HULC and MicroRNA-622 via Transfer by Extracellular Vesicles Regulates Cell Invasion and Migration in Human Pancreatic Cancer.
Takahashi K, Koyama K, Ota Y, Iwamoto H, Yamakita K, Fujii S, Kitano Y.
Front Oncol. 2020 Jun 23;10:1013. doi: 10.3389/fonc.2020.01013. eCollection 2020.
https://pubmed.ncbi.nlm.nih.gov/32656089/

Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth.
Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Yan I, Aso K, Fujii S, Patel T, Haneda M.
FEBS Open Bio. 2021 Dec;11(12):3276-3292. doi: 10.1002/2211-5463.13294. Epub 2021 Sep 22.
https://pubmed.ncbi.nlm.nih.gov/34510808/

Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response.
Itami-Matsumoto S, Hayakawa M, Uchida-Kobayashi S, Enomoto M, Tamori A, Mizuno K, Toyoda H, Tamura T, Akutsu T, Ochiya T, Kawada N, Murakami Y.
Biomedicines. 2019 Nov 3;7(4):87. doi: 10.3390/biomedicines7040087.
https://pubmed.ncbi.nlm.nih.gov/31684167/

Comprehensive analysis of liver and blood miRNA in precancerous conditions.
Umezu T, Tsuneyama K, Kanekura K, Hayakawa M, Tanahashi T, Kawano M, Taguchi YH, Toyoda H, Tamori A, Kuroda M, Murakami Y.
Sci Rep. 2020 Dec 10;10(1):21766. doi: 10.1038/s41598-020-78500-1.
https://pubmed.ncbi.nlm.nih.gov/33303811/

Exosome-mediated radiosensitizing effect on neighboring cancer cells via increase in intracellular levels of reactive oxygen species.
Nakaoka A, Nakahana M, Inubushi S, Akasaka H, Salah M, Fujita Y, Kubota H, Hassan M, Nishikawa R, Mukumoto N, Ishihara T, Miyawaki D, Sasayama T, Sasaki R.
Oncol Rep. 2021 Apr;45(4):13. doi: 10.3892/or.2021.7964. Epub 2021 Mar 2.
https://pubmed.ncbi.nlm.nih.gov/33649776/

Serum exosomal miR-638 is a prognostic marker of HCC via downregulation of VE-cadherin and ZO-1 of endothelial cells.
Yokota Y, Noda T, Okumura Y, Kobayashi S, Iwagami Y, Yamada D, Tomimaru Y, Akita H, Gotoh K, Takeda Y, Tanemura M, Murakami T, Umeshita K, Doki Y, Eguchi H.
Cancer Sci. 2021 Mar;112(3):1275-1288. doi: 10.1111/cas.14807. Epub 2021 Jan 29.
https://pubmed.ncbi.nlm.nih.gov/33426736/

Urinary MicroRNA-Based Diagnostic Model for Central Nervous System Tumors Using Nanowire Scaffolds.
Kitano Y, Aoki K, Ohka F, Yamazaki S, Motomura K, Tanahashi K, Hirano M, Naganawa T, Iida M, Shiraki Y, Nishikawa T, Shimizu H, Yamaguchi J, Maeda S, Suzuki H, Wakabayashi T, Baba Y, Yasui T, Natsume A.
ACS Appl Mater Interfaces. 2021 Apr 21;13(15):17316-17329. doi: 10.1021/acsami.1c01754. Epub 2021 Apr 1.
https://pubmed.ncbi.nlm.nih.gov/33793202/

Extracellular vesicles derived from radioresistant oral squamous cell carcinoma cells contribute to the acquisition of radioresistance via the miR-503-3p-BAK axis.
Yamana K, Inoue J, Yoshida R, Sakata J, Nakashima H, Arita H, Kawaguchi S, Gohara S, Nagao Y, Takeshita H, Maeshiro M, Liu R, Matsuoka Y, Hirayama M, Kawahara K, Nagata M, Hirosue A, Toya R, Murakami R, Kuwahara Y, Fukumoto M, Nakayama H.
J Extracell Vesicles. 2021 Dec;10(14):e12169. doi: 10.1002/jev2.12169.
https://pubmed.ncbi.nlm.nih.gov/34894384/

Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
Naiki-Ito A, Naiki T, Kato H, Iida K, Etani T, Nagayasu Y, Suzuki S, Yamashita Y, Inaguma S, Onishi M, Tanaka Y, Yasui T, Takahashi S.
Carcinogenesis. 2020 Aug 12;41(8):1145-1157. doi: 10.1093/carcin/bgz193.
https://pubmed.ncbi.nlm.nih.gov/31805186/

Suppression of intrahepatic cholangiocarcinoma cell growth by SKI via upregulation of the CDK inhibitor p21.
Kawamura E, Matsubara T, Daikoku A, Deguchi S, Kinoshita M, Yuasa H, Urushima H, Odagiri N, Motoyama H, Kotani K, Kozuka R, Hagihara A, Fujii H, Uchida-Kobayashi S, Tanaka S, Takemura S, Iwaisako K, Enomoto M, Taguchi YH, Tamori A, Kubo S, Ikeda K, Kawada N.
FEBS Open Bio. 2022 Dec;12(12):2122-2135. doi: 10.1002/2211-5463.13489. Epub 2022 Sep 26.
https://pubmed.ncbi.nlm.nih.gov/36114826/

Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells.
Nakahara M, Fujihara S, Iwama H, Takuma K, Oura K, Tadokoro T, Fujita K, Tani J, Morishita A, Kobara H, Himoto T, Masaki T.
Biomed Rep. 2022 Aug 3;17(4):78. doi: 10.3892/br.2022.1561. eCollection 2022 Oct.
https://pubmed.ncbi.nlm.nih.gov/36158319/

Independent verification of circulating miRNA as diagnostic biomarkers for urothelial carcinoma.
Urabe F, Matsuzaki J, Takeshita F, Kishida T, Ochiya T, Hirai K.
Cancer Sci. 2022 Oct;113(10):3510-3517. doi: 10.1111/cas.15496. Epub 2022 Aug 12.
https://pubmed.ncbi.nlm.nih.gov/35848873/

Prediction of tissue-of-origin of early stage cancers using serum miRNomes.
Matsuzaki J, Kato K, Oono K, Tsuchiya N, Sudo K, Shimomura A, Tamura K, Shiino S, Kinoshita T, Daiko H, Wada T, Katai H, Ochiai H, Kanemitsu Y, Takamaru H, Abe S, Saito Y, Boku N, Kondo S, Ueno H, Okusaka T, Shimada K, Ohe Y, Asakura K, Yoshida Y, Watanabe SI, Asano N, Kawai A, Ohno M, Narita Y, Ishikawa M, Kato T, Fujimoto H, Niida S, Sakamoto H, Takizawa S, Akiba T, Okanohara D, Shiraishi K, Kohno T, Takeshita F, Nakagama H, Ota N, Ochiya T; Project Team for Development and Diagnostic Technology for Detection of miRNA in Body Fluids.
JNCI Cancer Spectr. 2023 Jan 3;7(1):pkac080. doi: 10.1093/jncics/pkac080
https://pubmed.ncbi.nlm.nih.gov/36426871/

Serum miRNA-based Prediction of Axillary Lymph Node Metastasis in Breast Cancer.
Shiino S, Matsuzaki J, Shimomura A, Kawauchi J, Takizawa S, Sakamoto H, Aoki Y, Yoshida M, Tamura K, Kato K, Kinoshita T, Kitagawa Y, Ochiya T.
https://pubmed.ncbi.nlm.nih.gov/30482779/

Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer.
Hisakane K, Seike M, Sugano T, Matsuda K, Kashiwada T, Nakamichi S, Matsumoto M, Miyanaga A, Noro R, Kubota K, Gemma A.
Gene. 2023 Mar 20;857:147177.
https://pubmed.ncbi.nlm.nih.gov/36623674/

Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease
Takahisa Gono, Yuka Okazaki, Masataka Kuwana.
Rheumatology (Oxford). 2022 Feb 2;61(2):806-814.
https://pubmed.ncbi.nlm.nih.gov/33890985/

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Shi T, Iwama H, Fujita K, Kobara H, Nishiyama N, Fujihara S, Goda Y, Yoneyama H, Morishita A, Tani J, Yamada M, Nakahara M, Takuma K, Masaki T.
Int J Mol Sci. 2021 Dec 2;22(23):13071.
https://pubmed.ncbi.nlm.nih.gov/34884875/

Hepatocellular Carcinoma-associated microRNAs Induced by Hepatoma-derived Growth Factor Stimulation
Hirayuki Enomoto , Hideji Nakamura , Hiroki Nishikawa , Takashi Nishimura , Yoshinori Iwata , Shuhei Nishiguchi , Hiroko Iijima
In Vivo. 2020 Sep-Oct;34(5):2297-2301.
https://pubmed.ncbi.nlm.nih.gov/32871753/

NADPH oxidase 5 has a crucial role in cellular motility of colon cancer cells
Naoki Ashizawa , Hiroki Shimizu , Katsutoshi Shoda , Shinji Furuya , Hidenori Akaike , Naohiro Hosomura , Yoshihiko Kawaguchi , Hidetake Amemiya , Hiromichi Kawaida , Makoto Sudo , Shingo Inoue , Hiroshi Kono , Keita Katsurahara , Atsushi Shiozaki , Daisuke Ichikawa
Int J Oncol. 2021 Aug;59(2):63
https://pubmed.ncbi.nlm.nih.gov/34278462/

Investigation of miRNA expression profiles using cohort samples reveals potential early detectability of colorectal cancers by serum miR-26a-5p before clinical diagnosis.
Hishida A, Yamada H, Ando Y, Okugawa Y, Shiozawa M, Miyagi Y, Daigo Y, Toiyama Y, Shirai Y, Tanaka K, Kubo Y, Okada R, Nagayoshi M, Tamura T, Mori A, Kondo T, Hamajima N, Takeuchi K, Wakai K.
Oncol Lett. 2022 Mar;23(3):87.
https://pubmed.ncbi.nlm.nih.gov/35126729/

A novel combination of serum microRNAs for the detection of early gastric cancer.
Abe S, Matsuzaki J, Sudo K, Oda I, Katai H, Kato K, Takizawa S, Sakamoto H, Takeshita F, Niida S, Saito Y, Ochiya T.
Gastric Cancer. 2021 Jul;24(4):835-843.
https://pubmed.ncbi.nlm.nih.gov/33743111/

The effectiveness of plasma miR-33a-5p as a predictive biomarker for the efficacy of colorectal cancer chemotherapy.
Sasaki M, Ishikawa T, Ishiguro M, Okazaki S, Yamauchi S, Kikuchi A, Matsuyama T, Kawada K, Tokunaga M, Uetake H, Kinugasa Y.
Oncol Lett. 2021 Jun;21(6):489.
https://pubmed.ncbi.nlm.nih.gov/33968205/

Zinc ions negatively regulate proapoptotic signaling in cells expressing oncogenic mutant Ras.
Hironori Edamatsu
BioMetals. 2022 Apr;35(2):349-362.
https://pubmed.ncbi.nlm.nih.gov/35212861/

S100A8/A9 Induced by Interaction with Macrophages in Esophageal Squamous Cell Carcinoma Promotes the Migration and Invasion of Cancer Cells via Akt and p38 MAPK Pathways.
Tanigawa K, Tsukamoto S, Koma YI, Kitamura Y, Urakami S, Shimizu M, Fujikawa M, Kodama T, Nishio M, Shigeoka M, Kakeji Y, Yokozaki H.
Am J Pathol. 2022 Mar;192(3):536-552.
https://pubmed.ncbi.nlm.nih.gov/34954212/

Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
Hisakane K, Seike M, Sugano T, Yoshikawa A, Matsuda K, Takano N, Takahashi S, Noro R, Gemma A.
Thorac Cancer. 2021 Jun;12(11):1690-1698.
https://pubmed.ncbi.nlm.nih.gov/33939301/

Transcription Factor Homeobox D9 Drives the Malignant Phenotype of HPV18-Positive Cervical Cancer Cells via Binding to the Viral Early Promoter.
Hayashi S, Iwata T, Imagawa R, Sugawara M, Chen G, Tanimoto S, Sugawara Y, Tanaka I, Matsui T, Nishio H, Nakamura M, Katoh Y, Mori S, Kukimoto I, Aoki D.
Cancers (Basel). 2021 Sep 15;13(18):4613.
https://pubmed.ncbi.nlm.nih.gov/34572841/

Galectin-9 suppresses the tumor growth of colon cancer in vitro and in vivo
Asahiro Morishita, Kei Nomura, Joji Tani, Koji Fujita, Hisakazu Iwama, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Kyoko Oura, Taiga Chiyo, Shintaro Fujihara, Toshiro Niki, Mitsuomi Hirashima, Akira Nishiyama, Takashi Himoto, Tsutomu Masaki
Oncol Rep. 2021 Jun;45(6):105.
https://pubmed.ncbi.nlm.nih.gov/33907832/

PAI-1 derived from cancer-associated fibroblasts in esophageal squamous cell carcinoma promotes the invasion of cancer cells and the migration of macrophages
Hiroki Sakamoto, Yu-Ichiro Koma, Nobuhide Higashino, Takayuki Kodama, Kohei Tanigawa, Masaki Shimizu, Masataka Fujikawa, Mari Nishio, Manabu Shigeoka, Yoshihiro Kakeji, Hiroshi Yokozaki
Lab Invest 2021 Mar;101(3):353-368. doi: 10.1038/s41374-020-00512-2.
https://pubmed.ncbi.nlm.nih.gov/33311557/

HDGF enhances VEGF dependent angiogenesis and FGF 2 is a VEGF independent angiogenic factor in non small cell lung cancer
Ryoji Eguchi, Ichiro Wakabayashi
Oncol Rep. 2020 Jul;44(1):14-28. doi: 10.3892/or.2020.7580. Epub 2020 Apr 9
https://pubmed.ncbi.nlm.nih.gov/32319650

The Epitranscriptome m6A Writer METTL3 Promotes Chemo- And Radioresistance in Pancreatic Cancer Cells.
Taketo K, Konno M, Asai A, Koseki J, Toratani M, Satoh T, Doki Y, Mori M, Ishii H, Ogawa K.
Int J Oncol. 2018 Feb;52(2):621-629. doi: 10.3892/ijo.2017.4219. Epub 2017 Dec 7.
https://www.ncbi.nlm.nih.gov/pubmed/29345285

MicroRNA profiles involved in trifluridine resistance.
Tsunekuni K, Konno M, Asai A, Koseki J, Kobunai T, Takechi T, Doki Y, Mori M, Ishii H.
Oncotarget. 2017 May 23;8(32):53017-53027. doi: 10.18632/oncotarget.18078. eCollection 2017 Aug 8.
https://www.ncbi.nlm.nih.gov/pubmed/28881790

MicroRNA miR-374, a potential radiosensitizer for carbon ion beam radiotherapy.
Baek SJ, Sato K, Nishida N, Koseki J, Azuma R, Kawamoto K, Konno M, Hayashi K, Satoh T, Doki Y, Mori M, Ishii H, Ogawa K.
Oncol Rep. 2016 Nov;36(5):2946-2950. doi: 10.3892/or.2016.5122. Epub 2016 Sep 22.
https://www.ncbi.nlm.nih.gov/pubmed/27665739

Expression of circular RNA CDR1-AS in colon cancer cells increases cell surface PD-L1 protein levels.
Tanaka E, Miyakawa Y, Kishikawa T, Seimiya T, Iwata T, Funato K, Odawara N, Sekiba K, Yamagami M, Suzuki T, Ishibashi R, Otsuka M, Koike K.
Oncol Rep. 2019 Oct;42(4):1459-1466. doi: 10.3892/or.2019.7244. Epub 2019 Jul 19.
https://www.ncbi.nlm.nih.gov/pubmed/31322270

Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer
Sonohara F, Yamada S, Takeda S, Hayashi M, Suenaga M, Sunagawa Y, Tashiro M, Takami H, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y.
Anticancer Res. 2020 Apr;40(4):1843-1853. doi: 10.21873/anticanres.14138
https://www.ncbi.nlm.nih.gov/pubmed/32234872

Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease.
Yamamoto Y, Kondo S, Matsuzaki J, Esaki M, Okusaka T, Shimada K, Murakami Y, Enomoto M, Tamori A, Kato K, Aoki Y, Takizawa S, Sakamoto H, Niida S, Takeshita F, Ochiya T
Hepatol Commun. 2019 Dec 19;4(2):284-297. doi: 10.1002/hep4.1451. eCollection 2020 Feb.
https://www.ncbi.nlm.nih.gov/pubmed/32025611

Peripheral neuropathy from paclitaxel: risk prediction by serum microRNAs.
Noda-Narita S, Shimomura A, Tanabe Y, Kawauchi J, Matsuzaki J, Takizawa S, Aoki Y, Shimizu C, Tamura K, Ochiya T
BMJ Support Palliat Care. 2020 Jan 14. pii: bmjspcare-2019-001900. doi: 10.1136/bmjspcare-2019-001900.
https://www.ncbi.nlm.nih.gov/pubmed/31937590

Brain metastasis-related microRNAs in patients with advanced breast cancer.
Sato J, Shimomura A, Kawauchi J, Matsuzaki J, Yamamoto Y, Takizawa S, Sakamoto H, Ohno M, Narita Y, Ochiya T, Tamura K.
PLoS One. 2019 Oct 11;14(10):e0221538. doi: 10.1371/journal.pone.0221538. eCollection 2019
https://www.ncbi.nlm.nih.gov/pubmed/31603918

Serum microRNA profile enables preoperative diagnosis of uterine leiomyosarcoma.
Yokoi A, Matsuzaki J, Yamamoto Y, Tate K, Yoneoka Y, Shimizu H, Uehara T, Ishikawa M, Takizawa S, Aoki Y, Kato K, Kato T, Ochiya T
Cancer Sci. 2019 Dec;110(12):3718-3726. doi: 10.1111/cas.14215. Epub 2019 Nov 16
https://www.ncbi.nlm.nih.gov/pubmed/31599471

A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy.
Asakura K, Kadota T, Matsuzaki J, Yoshida Y, Yamamoto Y, Nakagawa K, Takizawa S, Aoki Y, Nakamura E, Miura J, Sakamoto H, Kato K, Watanabe S, Ochiya T
Commun Biol. 2020 Mar 19;3(1):134. doi: 10.1038/s42003-020-0863-y
https://www.ncbi.nlm.nih.gov/pubmed/32193503

Plasma microRNA profiles: identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer.
Nishibeppu K, Komatsu S, Imamura T, Kiuchi J, Kishimoto T, Arita T, Kosuga T, Konishi H, Kubota T, Shiozaki A, Fujiwara H, Okamoto K, Otsuji E
Sci Rep. 2020 Feb 21;10(1):3161. doi: 10.1038/s41598-020-59939-8
https://www.ncbi.nlm.nih.gov/pubmed/32081926

Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma.
Ohno M, Matsuzaki J, Kawauchi J, Aoki Y, Miura J, Takizawa S, Kato K, Sakamoto H, Matsushita Y, Takahashi M, Miyakita Y, Ichimura K, Narita Y, Ochiya T.
JAMA Netw Open. 2019 Dec 2;2(12):e1916953. doi: 10.1001/jamanetworkopen.2019.16953
https://www.ncbi.nlm.nih.gov/pubmed/31808923

Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer
Satomi-Tsushita N, Shimomura A, Matsuzaki J, Yamamoto Y, Kawauchi J, Takizawa S, Aoki Y, Sakamoto H, Kato K, Shimizu C, Ochiya T, Tamura K.
PLoS One. 2019 Sep 4;14(9):e0222024. doi: 10.1371/journal.pone.0222024. eCollection 2019
https://www.ncbi.nlm.nih.gov/pubmed/31483849

Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling
Sudo K, Kato K, Matsuzaki J, Boku N, Abe S, Saito Y, Daiko H, Takizawa S, Aoki Y, Sakamoto H, Niida S, Takeshita F, Fukuda T, Ochiya T
JAMA Netw Open. 2019 May 3;2(5):e194573. doi: 10.1001/jamanetworkopen.2019.4573
https://www.ncbi.nlm.nih.gov/pubmed/31125107

Distinct methylation levels of mature microRNAs in gastrointestinal cancers
Masamitsu Konno, Jun Koseki, Ayumu Asai, Akira Yamagata, Teppei Shimamura,Daisuke Motooka, Daisuke Okuzaki, Koichi Kawamoto, Tsunekazu Mizushima, Hidetoshi Eguchi,Shuji Takiguchi, Taroh Satoh, Koshi Mimori, Takahiro Ochiya,Yuichiro Doki, Ken Ofusa, Masaki Mori &Hideshi Ishii
nature COMMUNICATIONS 2019 Aug 29;10(1):3888. doi: 10.1038/s41467-019-11826-1
https://www.ncbi.nlm.nih.gov/pubmed/31467274

Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer.
Urabe F, Matsuzaki J, Yamamoto Y Kimura T, Hara T, Ichikawa M, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Egawa S, Fujimoto H, Ochiya T.
Clin Cancer Res. 2019 Feb 26. pii: clincanres.2849.2018. doi: 10.1158/1078-0432.CCR-18-2849.
https://www.ncbi.nlm.nih.gov/pubmed/30808771

MicroRNA profiles during galectin-9-induced apoptosis of pancreatic cancer cells.
Okura R, Fujihara S, Iwama H, Morishita A, Chiyo T, Watanabe M, Hirose K, Kobayashi K, Fujimori T, Kato K, Kamada H, Kobara H, Mori H, Niki T, Hirashima M, Okano K, Suzuki Y, Masaki T.
Oncol Lett. 2018 Jan;15(1):407-414.
https://www.ncbi.nlm.nih.gov/pubmed/29387226

MicroRNA-8073: Tumor suppressor and potential therapeutic treatment.
Mizoguchi A, Takayama A, Arai T, Kawauchi J, Sudo H.
PLoS One. 2018 Dec 27;13(12):e0209750. doi: 10.1371/journal.pone.0209750. eCollection 2018.
https://www.ncbi.nlm.nih.gov/pubmed/30589909

Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer.
Usuba W, Urabe F, Yamamoto Y, Matsuzaki J, Sasaki H, Ichikawa M, Takizawa S, Aoki Y, Niida S, Kato K, Egawa S, Chikaraishi T, Fujimoto H, Ochiya T.
Cancer Sci. 2018 Nov 1.
https://www.ncbi.nlm.nih.gov/pubmed/30382619

Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer.
Kral J, Korenkova V, Novosadova V, Langerova L, Schneiderova M, Liska V, Levy M, Veskrnova V, Spicak J, Opattova A, Jiraskova K, Vymetalkova V, Vodicka P, Slyskova J.
Carcinogenesis. 2018 Oct 1. doi: 10.1093/carcin/bgy100
https://www.ncbi.nlm.nih.gov/pubmed/30277504

A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
Inamoto T, Uehara H, Akao Y, Ibuki N, Komura K, Takahara K, Takai T, Uchimoto T, Saito K, Tanda N, Yoshikawa Y, Minami K, Hirano H, Nomi H, Kato R, Hayashi T, Azuma H.
Dis Markers. 2018 Jun 20;2018:5468672. doi: 10.1155/2018/5468672. eCollection 2018
https://www.ncbi.nlm.nih.gov/pubmed/30026881

Integrated extracellular microRNA profiling for ovarian cancer screening.
Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda S, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T.
Nat Commun. 2018 Oct 17;9(1):4319. doi: 10.1038/s41467-018-06434-4.
https://www.ncbi.nlm.nih.gov/pubmed/30333487

Circulating microRNAs as potential biomarkers to detect transformation of Barrett's oesophagus to oesophageal adenocarcinoma.
Matsuzaki J, Suzuki H.
BMJ Open Gastroenterol. 2017 Sep 8;4(1):e000160.
https://www.ncbi.nlm.nih.gov/pubmed/29177063

Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer.
Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T, Kiuchi J, Nishibeppu K, Konishi H, Shiozaki A, Morimura R, Ikoma H, Ochiai T, Okamoto K, Taniguchi H, Otsuji E.
Sci Rep. 2017 Jul 18;7(1):5708
https://www.ncbi.nlm.nih.gov/pubmed/28720759

Cluster microRNAs miR-194 and miR-215 suppress the tumorigenicity of intestinal tumor organoids.
Nakaoka T, Saito Y, Shimamoto Y, Muramatsu T, Kimura M, Kanai Y, Saito H.
Cancer Sci. 2017 Jan 16
https://www.ncbi.nlm.nih.gov/pubmed/28092415

Amigo2-upregulation in Tumour Cells Facilitates Their Attachment to Liver Endothelial Cells Resulting in Liver Metastases.
Kanda Y, Osaki M, Onuma K, Sonoda A, Kobayashi M, Hamada J, Nicolson GL, Ochiya T, Okada F.
Sci Rep. 2017 Mar 8;7:43567.
https://www.ncbi.nlm.nih.gov/pubmed/28272394

The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S, Morishita A, Ogawa K, Tadokoro T, Chiyo T, Kato K, Kobara H, Mori H, Iwama H, Masaki T.
Oncotarget. 2017 Jan 31;8(5):8536-8549.
https://www.ncbi.nlm.nih.gov/pubmed/28052030

Repression of microRNA Function Mediates Inflammation-associated Colon Tumorigenesis.
Yoshikawa T, Wu J, Otsuka M, Kishikawa T, Suzuki N, Takata A, Ohno M, Ishibashi R, Yamagami M, Nakagawa R, Kato N, Miyazawa M, Han J, Koike K.
Gastroenterology. 2016 Nov 5. pii: S0016-5085(16)35322-7
https://www.ncbi.nlm.nih.gov/pubmed/27825961

microRNA-mediated resistance to hypoglycemia in the HepG2 human hepatoma cell line.
microRNA-mediated resistance to hypoglycemia in the HepG2 human hepatoma cell line.
BMC Cancer. 2016 Sep 15;16(1):732.
https://www.ncbi.nlm.nih.gov/pubmed/27629773

Circulating miR-223 in Oral Cancer: Its Potential as a Novel Diagnostic Biomarker and Therapeutic Target.
Tachibana H, Sho R, Takeda Y, Zhang X, Yoshida Y, Narimatsu H, Otani K, Ishikawa S, Fukao A, Asao H, Iino M.
PLoS One. 2016 Jul 21;11(7):e0159693.
https://www.ncbi.nlm.nih.gov/pubmed/27441818

Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.
Sato S, Katsushima K, Shinjo K, Hatanaka A, Ohka F, Suzuki S, Naiki-Ito A, Soga N, Takahashi S, Kondo Y.
Cancer Res. 2016 Jul 15;76(14):4192-204.
https://www.ncbi.nlm.nih.gov/pubmed/27216188

Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms.
Horiguchi H, Kobune M, Kikuchi S, Yoshida M, Murata M, Murase K, Iyama S, Takada K, Sato T, Ono K, Hashimoto A, Tatekoshi A, Kamihara Y, Kawano Y, Miyanishi K, Sawada N, Kato J.
Haematologica. 2016 Apr;101(4):437-47
http://www.ncbi.nlm.nih.gov/pubmed/26802051

Novel combination of serum microRNA for detecting breast cancer in the early stage.
Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, Shimizu C, Fujiwara Y, Kinoshita T, Tamura K, Ochiya T.
Cancer Sci. 2016 Mar;107(3):326-34.
http://www.ncbi.nlm.nih.gov/pubmed/26749252

The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin.
Oncol Rep. 2016 Mar;35(3):1582-92.
Kato K, Iwama H, Yamashita T, Kobayashi K, Fujihara S, Fujimori T, Kamada H, Kobara H, Masaki T.
https://www.ncbi.nlm.nih.gov/pubmed/26708419

Microarray Technology and Its Applications for Detecting Plasma microRNA Biomarkers in Digestive Tract Cancers.
Konishi H, Ichikawa D, Arita T, Otsuji E.
Methods Mol Biol. 2016;1368:99-109.
http://www.ncbi.nlm.nih.gov/pubmed/26614071

Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies.
Oncol Rep. 2015 Dec;34(6):2987-96.
Fujimori T, Kato K, Fujihara S, Iwama H, Yamashita T, Kobayashi K, Kamada H, Morishita A, Kobara H, Mori H, Okano K, Suzuki Y, Masaki T.
https://www.ncbi.nlm.nih.gov/pubmed/26398221

Differences in miRNA expression profiles between GIST and leiomyoma in human samples acquired by submucosal tunneling biopsy.
Fujita K, Kobara H, Mori H, Fujihara S, Chiyo T, Matsunaga T, Nishiyama N, Ayaki M, Yachida T, Morishita A, Fujiwara M, Okano K, Suzuki Y, Iwama H, Masaki T.
Endosc Int Open. 2015 Dec;3(6):E665-71
http://www.ncbi.nlm.nih.gov/pubmed/26716134

Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer.
Miyamae M, Komatsu S, Ichikawa D, Kawaguchi T, Hirajima S, Okajima W, Ohashi T, Imamura T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Ochiai T, Okamoto K, Taniguchi H, Otsuji E.
Br J Cancer. 2015 Nov 17;113(10):1467-76.
http://www.ncbi.nlm.nih.gov/pubmed/26505678

Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays.
Ono S, Lam S, Nagahara M, Hoon DS.
J Clin Med. 2015 Oct 23;4(10):1890-907.
http://www.ncbi.nlm.nih.gov/pubmed/26512704

Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest.
Kobayashi K, Morishita A, Iwama H, Fujita K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H, Niki T, Hirashima M, Okano K, Suzuki Y, Masaki T.
Oncol Rep. 2015 Oct;34(4):1761-70.
https://www.ncbi.nlm.nih.gov/pubmed/26260906

Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo.
Fujita K, Iwama H, Sakamoto T, Okura R, Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, Nomura T, Tani J, Miyoshi H, Morishita A, Yoneyama H, Yamana Y, Himoto T, Okano K, Suzuki Y, Niki T, Hirashima M, Masaki T.
Int J Oncol. 2015;46(6):2419-30.
https://www.ncbi.nlm.nih.gov/pubmed/25823465

SUV420H2 suppresses breast cancer cell invasion through down regulation of the SH2 domain-containing focal adhesion protein tensin-3.
Shinchi Y, Hieda M, Nishioka Y, Matsumoto A, Yokoyama Y, Kimura H, Matsuura S, Matsuura N.
Exp Cell Res. 2015 May 15;334(1):90-9.
http://www.ncbi.nlm.nih.gov/pubmed/25814362

Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells.
Yamashita R, Sato M, Kakumu T, Hase T, Yogo N, Maruyama E, Sekido Y, Kondo M, Hasegawa Y.
Cancer Med. 2015 Apr;4(4):551-64.
http://www.ncbi.nlm.nih.gov/pubmed/25641933

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer.
Hiraki M, Nishimura J, Takahashi H, Wu X, Takahashi Y, Miyo M, Nishida N, Uemura M, Hata T, Takemasa I, Mizushima T, Soh JW, Doki Y, Mori M, Yamamoto H.
Mol Ther Nucleic Acids. 2015 Mar 10;4:e231.
http://www.ncbi.nlm.nih.gov/pubmed/25756961

Clustered MicroRNAs of the Epstein-Barr Virus Cooperatively Downregulate an Epithelial Cell-Specific Metastasis Suppressor.
Kanda T, Miyata M, Kano M, Kondo S, Yoshizaki T, Iizasa H.
J Virol. 2015 Mar 1;89(5):2684-97.
http://www.ncbi.nlm.nih.gov/pubmed/25520514

MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers.
Kojima M, Sudo H, Kawauchi J, Takizawa S, Kondou S, Nobumasa H, Ochiai A.
PLoS One. 2015 Feb 23;10(2):e0118220.
http://www.ncbi.nlm.nih.gov/pubmed/25706130

Contextual niche signals towards colorectal tumor progression by mesenchymal stem cell in the mouse xenograft model.
Nakagaki S, Arimura Y, Nagaishi K, Isshiki H, Nasuno M, Watanabe S, Idogawa M, Yamashita K, Naishiro Y, Adachi Y, Suzuki H, Fujimiya M, Imai K, Shinomura Y.
J Gastroenterol. 2015 Feb 14.
http://www.ncbi.nlm.nih.gov/pubmed/25680886

Tropomodulin 1 Expression Driven by NF-κB Enhances Breast Cancer Growth.
Ito-Kureha T, Koshikawa N, Yamamoto M, Semba K, Yamaguchi N, Yamamoto T, Seiki M, Inoue J.
Cancer Res. 2015 Jan 1;75(1):62-72.
http://www.ncbi.nlm.nih.gov/pubmed/25398440

Involvement of miR-518c-5p to growth and metastasis in oral cancer.
Kinouchi M, Uchida D, Kuribayashi N, Tamatani T, Nagai H, Miyamoto Y. 
PLoS One. 2014 Dec 23;9(12):e115936.
http://www.ncbi.nlm.nih.gov/pubmed/25536052

Plasma microRNA profiles: identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma.
Komatsu S, Ichikawa D, Hirajima S, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Arita T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Yagi N, Otsuji E.
Br J Cancer. 2014 Oct 14;111(8):1614-24.
http://www.ncbi.nlm.nih.gov/pubmed/25117812

MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.
Hasegawa S, Eguchi H, Nagano H, Konno M, Tomimaru Y, Wada H, Hama N, Kawamoto K, Kobayashi S, Nishida N, Koseki J, Nishimura T, Gotoh N, Ohno S, Yabuta N, Nojima H, Mori M, Doki Y, Ishii H.
Br J Cancer. 2014 Oct 14;111(8):1572-80.
http://www.ncbi.nlm.nih.gov/pubmed/25117811

Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
Takaki Y, Saito Y, Takasugi A, Toshimitsu K, Yamada S, Muramatsu T, Kimura M, Sugiyama K, Suzuki H, Arai E, Ojima H, Kanai Y, Saito H.
Cancer Sci. 2014 Oct;105(10):1254-60.
http://www.ncbi.nlm.nih.gov/pubmed/25117675

Guanine nucleotide-binding protein 1 is one of the key molecules contributing to cancer cell radioresistance.
Fukumoto M, Amanuma T, Kuwahara Y, Shimura T, Suzuki M, Mori S, Kumamoto H, Saito Y, Ohkubo Y, Duan Z, Sano K, Oguchi T, Kainuma K, Usami S, Kinoshita K, Lee I, Fukumoto M.
Cancer Sci. 2014 Oct;105(10):1351-9.
http://www.ncbi.nlm.nih.gov/pubmed/25098609

Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells.
Ono M, Kosaka N, Tominaga N, Yoshioka Y, Takeshita F, Takahashi RU, Yoshida M, Tsuda H, Tamura K, Ochiya T.
Sci Signal. 2014 Jul 1;7(332)
http://www.ncbi.nlm.nih.gov/pubmed/24985346

MicroRNA-203 inhibits the progression of esophageal squamous cell carcinoma with restored epithelial tissue architecture in vivo.
Okumura T, Shimada Y, Moriyama M, Takei Y, Omura T, Sekine S, Nagata T, Shimizu K, Tsukada K.
Int J Oncol. 2014 Jun;44(6):1923-32.
http://www.ncbi.nlm.nih.gov/pubmed/24692008

Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells.
Hibino S, Saito Y, Muramatsu T, Otani A, Kasai Y, Kimura M, Saito H.
Oncogenesis. 2014 May 26;3:e104.
http://www.ncbi.nlm.nih.gov/pubmed/24861464

Identification of signaling pathways modulated by RHBDD2 in breast cancer cells: a link to the unfolded protein response.
Lacunza E, Rabassa ME, Canzoneri R, Pellon-Maison M, Croce MV, Aldaz CM, Abba MC.
Cell Stress Chaperones. 2014 May;19(3):379-88.
http://www.ncbi.nlm.nih.gov/pubmed/24078384

CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.
Komiya E, Ohnuma K, Yamazaki H, Hatano R, Iwata S, Okamoto T, Dang NH, Yamada T, Morimoto C.
Biochem Biophys Res Commun. 2014 May 16;447(4):609-15.
http://www.ncbi.nlm.nih.gov/pubmed/24747072

Matrix metalloproteinase (MMP)-9 in cancer-associated fibroblasts (CAFs) is suppressed by omega-3 polyunsaturated fatty acids in vitro and in vivo.
Taguchi A, Kawana K, Tomio K, Yamashita A, Isobe Y, Nagasaka K, Koga K, Inoue T, Nishida H, Kojima S, Adachi K, Matsumoto Y, Arimoto T, Wada-Hiraike O, Oda K, Kang JX, Arai H, Arita M, Osuga Y, Fujii T.
PLoS One. 2014 Feb 27;9(2):e89605.
http://www.ncbi.nlm.nih.gov/pubmed/24586907

Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
Omura T, Shimada Y, Nagata T, Okumura T, Fukuoka J, Yamagishi F, Tajika S, Nakajima S, Kawabe A, Tsukada K.
Oncol Rep. 2014 Feb;31(2):613-8.
http://www.ncbi.nlm.nih.gov/pubmed/24317477

Gene expression analysis using a highly sensitive DNA microarray for colorectal cancer screening.
Koga Y, Yamazaki N, Takizawa S, Kawauchi J, Nomura O, Yamamoto S, Saito N, Kakugawa Y, Otake Y, Matsumoto M, Matsumura Y.
Anticancer Res. 2014 Jan;34(1):169-76.
http://www.ncbi.nlm.nih.gov/pubmed/24403458

Role of aquaporin-5 in gallbladder carcinoma.
Sekine S, Shimada Y, Nagata T, Sawada S, Yoshioka I, Matsui K, Moriyama M, Omura T, Osawa S, Shibuya K, Hashimoto I, Watanabe T, Hojo S, Hori R, Okumura T, Yoshida T, Tsukada K.
Eur Surg Res. 2013;51(3-4):108-17.
http://www.ncbi.nlm.nih.gov/pubmed/24217644

Differential gene expression in cholesteatoma by DNA chip analysis.
Macias JD, Gerkin RD, Locke D, Macias MP.
Laryngoscope. 2013 Oct;123 Suppl S5:S1-21.
http://www.ncbi.nlm.nih.gov/pubmed/23670528

Gene expression of bone morphogenic protein 8B in the primary site, peripheral blood and bone marrow of patients with gastric cancer.
Mima K, Fukagawa T, Kurashige J, Takano Y, Uchi R, Ueo H, Matsumura T, Ishibashi M, Sawada G, Takahashi Y, Akiyoshi S, Eguchi H, Sudo T, Sugimachi K, Watanabe M, Ishii H, Mori M, Baba H, Sasako M, Mimori K.
Oncol Lett. 2013 Aug;6(2):387-392.
http://www.ncbi.nlm.nih.gov/pubmed/24137334

MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells.
Qu Y, Li WC, Hellem MR, Rostad K, Popa M, McCormack E, Oyan AM, Kalland KH, Ke XS.
Int J Cancer. 2013 Aug 1;133(3):544-55.
http://www.ncbi.nlm.nih.gov/pubmed/23354685

Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M, Sumi K, Kasahara T, Tago K.
PLoS One. 2013;8(1):e52844.
http://www.ncbi.nlm.nih.gov/pubmed/23300995

MiR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T, Fujii Y, Yamashita H.
Endocr Relat Cancer. 2013 Feb 18;20(1):91-102.
http://www.ncbi.nlm.nih.gov/pubmed/23183268

Identification of miR-30d as a novel prognostic maker of prostate cancer.
Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, Nagashima Y, Kubota Y, Ishiguro H.
Oncotarget. 2012 Nov;3(11):1455-71.
http://www.ncbi.nlm.nih.gov/pubmed/23231923

Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases.
Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, Sasako M, Maehara Y, Mimori K, Mori M.
Br J Cancer. 2012 Oct 9;107(8):1345-53.
http://www.ncbi.nlm.nih.gov/pubmed/22955854

High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer.
Giovannetti E, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE, Gallá V, Sudo H, Falcone A, Campani D, Boggi U, Peters GJ.
PLoS One. 2012;7(11):e49145.
http://www.ncbi.nlm.nih.gov/pubmed/23155457

Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.
Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G, Shimizu K.
PLoS One. 2012;7(2):e31422.
http://www.ncbi.nlm.nih.gov/pubmed/22384020

Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
Horio M, Sato M, Takeyama Y, Elshazley M, Yamashita R, Hase T, Yoshida K, Usami N, Yokoi K, Sekido Y, Kondo M, Toyokuni S, Gazdar AF, Minna JD, Hasegawa Y.
Ann Surg Oncol. 2012 Jul;19 Suppl 3:S634-45.
http://www.ncbi.nlm.nih.gov/pubmed/22086445

The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo.
Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, Kobara H, Mori H, Himoto T, Okano K, Suzuki Y, Murao K, Masaki T.
Mol Cancer Ther. 2012 Mar;11(3):549-60. 
http://www.ncbi.nlm.nih.gov/pubmed/22222629

Fibroblast growth factor-2 is an important factor that maintains cellular immaturity and contributes to aggressiveness of osteosarcoma.
Shimizu T, Ishikawa T, Iwai S, Ueki A, Sugihara E, Onishi N, Kuninaka S, Miyamoto T, Toyama Y, Ijiri H, Mori H, Matsuzaki Y, Yaguchi T, Nishio H, Kawakami Y, Ikeda Y, Saya H.
Mol Cancer Res. 2012 Mar;10(3):454-68. 
http://www.ncbi.nlm.nih.gov/pubmed/22228819

Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma.
Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, Morimura R, Nagata H, Arita T, Kawaguchi T, Hirashima S, Fujiwara H, Okamoto K, Otsuji E.
Br J Cancer. 2012 Feb 14;106(4):740-7.
http://www.ncbi.nlm.nih.gov/pubmed/22262318

DNA damage signaling triggers degradation of histone methyltransferases through APC/C(Cdh1) in senescent cells.
Takahashi A, Imai Y, Yamakoshi K, Kuninaka S, Ohtani N, Yoshimoto S, Hori S, Tachibana M, Anderton E, Takeuchi T, Shinkai Y, Peters G, Saya H, Hara E.
Mol Cell. 2012 Jan 13;45(1):123-31. 
http://www.ncbi.nlm.nih.gov/pubmed/22178396

MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples.
Osawa S, Shimada Y, Sekine S, Okumura T, Nagata T, Fukuoka J, Tsukada K.
Oncol Lett. 2011 Jul;2(4):613-619.
http://www.ncbi.nlm.nih.gov/pubmed/22848236

miR-22 represses cancer progression by inducing cellular senescence.
Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H.
J Cell Biol. 2011 Apr 18;193(2):409-24.
http://www.ncbi.nlm.nih.gov/pubmed/21502362

Identification of altered MicroRNA expression patterns in synovial sarcoma.
Hisaoka M, Matsuyama A, Nagao Y, Luan L, Kuroda T, Akiyama H, Kondo S, Hashimoto H.
Genes Chromosomes Cancer. 2011 Mar;50(3):137-45.
http://www.ncbi.nlm.nih.gov/pubmed/21213367

MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria.
Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S, Shimizu K.
PLoS One. 2011 Jan 27;6(1):e16435.
http://www.ncbi.nlm.nih.gov/pubmed/21298008

MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1).
Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G.
J Biol Chem. 2011 Jan 7;286(1):420-8.
http://www.ncbi.nlm.nih.gov/pubmed/21044961

Circadian disruption accelerates tumor growth and angio/stromagenesis through a Wnt signaling pathway.
Yasuniwa Y, Izumi H, Wang KY, Shimajiri S, Sasaguri Y, Kawai K, Kasai H, Shimada T, Miyake K, Kashiwagi E, Hirano G, Kidani A, Akiyama M, Han B, Wu Y, Ieiri I, Higuchi S, Kohno K.
PLoS One. 2010 Dec 23;5(12):e15330.
http://www.ncbi.nlm.nih.gov/pubmed/21203463

c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis.
Shimizu T, Ishikawa T, Sugihara E, Kuninaka S, Miyamoto T, Mabuchi Y, Matsuzaki Y, Tsunoda T, Miya F, Morioka H, Nakayama R, Kobayashi E, Toyama Y, Kawai A, Ichikawa H, Hasegawa T, Okada S, Ito T, Ikeda Y, Suda T, Saya H.
Oncogene. 2010 Oct 21;29(42):5687-99. 
http://www.ncbi.nlm.nih.gov/pubmed/20676132

Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model.
Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, Kizaka-Kondoh S, Aoki M, Taketo MM.
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13063-8
http://www.ncbi.nlm.nih.gov/pubmed/20616008

Clinical application of cytokine-related gene polymorphism analysis using a newly developed DNA chip in critically ill patients.
Otani S, Oda S, Sadahiro T, Nakamura M, Watanabe E, Nakada TA, Abe R, Tokuhisa T, Hirasawa H.
Clin Biochem. 2009 Sep;42(13-14):1387-93. 
http://www.ncbi.nlm.nih.gov/pubmed/19527699

cDNA microarray analysis of esophageal cancer: discoveries and prospects.
Shimada Y, Sato F, Shimizu K, Tsujimoto G, Tsukada K.
Gen Thorac Cardiovasc Surg. 2009 Jul;57(7):347-56. 
http://www.ncbi.nlm.nih.gov/pubmed/19597924